A Field Transformed in Just a Few Years

For most of the history of Devic's Disease, patients and clinicians had no approved treatments — only off-label immunosuppressants borrowed from other autoimmune conditions. That changed decisively between 2019 and 2021 with a wave of FDA approvals specifically for Neuromyelitis Optica Spectrum Disorder (NMOSD). Understanding these milestones helps patients and caregivers appreciate how rapidly the field has advanced — and what to watch for next.

The FDA Approval Timeline for NMOSD

June 2019: Eculizumab (Soliris) — The First Approved NMO Therapy

Eculizumab, developed by Alexion Pharmaceuticals, became the first drug ever specifically approved by the FDA for NMOSD in AQP4-IgG seropositive adults. It works by inhibiting complement protein C5, blocking the destructive complement cascade triggered by AQP4-IgG antibodies. The pivotal PREVENT trial demonstrated a significant reduction in relapse risk compared to placebo. This approval marked a historic moment for the NMO community after decades of no approved options.

June 2020: Inebilizumab (Uplizna) — B-Cell Depletion Approved

Inebilizumab targets CD19, a marker on B cells and plasmablasts — the cells responsible for producing AQP4-IgG antibodies. By depleting a broader population of B lineage cells than anti-CD20 agents (which target CD20), inebilizumab aims for deeper and more durable antibody reduction. The N-MOmentum trial supported its approval in AQP4-IgG seropositive adults.

August 2020: Satralizumab (Enspryng) — An IL-6 Blocker with Self-Injection Option

Satralizumab, from Chugai/Roche, blocks the interleukin-6 (IL-6) receptor. IL-6 plays a key role in promoting the survival of antibody-producing plasma cells and driving CNS inflammation in NMO. Importantly, satralizumab is administered subcutaneously — allowing patients to self-inject at home, which is a significant quality-of-life advantage compared to infusion-based therapies. The SAkuraSky and SAkuraStar trials demonstrated efficacy in AQP4-IgG positive patients.

The Growing Landscape: Therapies Under Investigation

The approval of three biologics in under two years catalyzed further research, and several additional agents are in various stages of clinical development for NMOSD:

  • Rozanolixizumab: An anti-FcRn antibody that reduces circulating IgG levels (including AQP4-IgG) by blocking the neonatal Fc receptor responsible for IgG recycling. Phase 2/3 trials are ongoing for NMOSD.
  • Telitacicept: A dual-target biologic blocking BAFF and APRIL, two cytokines that sustain B cell and plasma cell survival. Being studied in NMOSD with early promising signals.
  • CAR-T cell therapy: Experimental approaches targeting autoreactive B cells are in early-stage investigation in autoimmune conditions including NMOSD.
  • Ublituximab (Briumvi): An anti-CD20 agent approved for MS, currently being evaluated more formally in NMOSD populations.

MOGAD: Still Awaiting Specific Approvals

Despite the progress in AQP4-IgG positive NMOSD, patients with MOG-antibody associated disease (MOGAD) still have no specifically approved therapy. This remains an active area of research urgency. Several trials are enrolling MOGAD patients specifically, including studies of inebilizumab and rozanolixizumab in this population.

Biomarker Research: Tracking Disease Without Waiting for Attacks

Beyond treatment approvals, significant scientific progress has been made in identifying blood-based biomarkers that can measure disease activity and treatment response:

  • Serum GFAP (glial fibrillary acidic protein): Elevated during NMO attacks and correlates with attack severity; levels may predict disability outcomes.
  • Neurofilament light chain (NfL): A marker of axonal damage, useful for monitoring neurological injury over time.
  • AQP4-IgG titers: Some research suggests that antibody titer changes may correlate with treatment response and relapse risk, though clinical use remains under investigation.

Advocacy and Policy Progress

The NMO advocacy community — led by organizations such as the Guthy-Jackson Charitable Foundation — has played a pivotal role in accelerating research funding and regulatory attention to this rare disease. NMO's designation as an orphan disease has facilitated FDA fast-track designations for several of the therapies discussed above, significantly shortening development timelines.

Ongoing advocacy efforts are focused on improving access to the approved biologics — which carry high list prices — for patients in lower-income countries and those without adequate insurance coverage.

Looking Ahead

The next frontier for NMO research lies in tolerization strategies — approaches that could retrain the immune system to stop producing AQP4-IgG antibodies permanently, potentially offering patients a true remission rather than ongoing suppression. While still largely experimental, early-phase trials are beginning to explore antigen-specific tolerance induction. For a disease that had no approved treatments just a decade ago, the pace of progress offers genuine hope.